STL Index for: Sussman Gordon
Urticaria is a common, mast-cell-driven disease, characterized clinically by the development of wheals, angioedema, or both. A large body of data has demonstrated that omalizumab, a biologic agent, is safe and effective in the treatment of H1- antihistamine refractory urticaria and should be considered as a third-line agent, with cyclosporin A reserved for fourth-line therapy.
Bilastine has a proven, long-term safety record with use by over 71 million patients in over 104 countries. This article describes the evolution from first generation antihistamines, second generation antihistamines, and where Bilastine comes in.
Omalizumab has emerged as a very promising treatment option for patients with CSU (Chronic spontaneous urticaria).This editorial reviews mechanisms of action of omalizumab, efficacy, cost and potential side effect profile.